Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Harvest Technology enters defence industry, scores contract with secret EU nation
    • News

    Harvest Technology enters defence industry, scores contract with secret EU nation

    If you’ve been following the war in Ukraine, one thing that the greater world has woken up to is the difference high-intelligence technology makes. The use of video communications for real-time targeting and troop movements by the undermanned Ukrainians has been astonishing. Looking to assist in this area (not for Ukraine), communications tech company Harvest

    Read More
    Public
  • Wide Open Agriculture teams up with My Foodie Box to enter East Australia market
    • News

    Wide Open Agriculture teams up with My Foodie Box to enter East Australia market

    Many of our favourite indulgences have a plant-based alternative now, be it meat or milk. Evidently, there is a growing market for plant-based foods, and food companies are all for milking this opportunity. After securing a spot with the first Coles Local launching in Western Australia, regenerative food and agriculture company Wide Open Agriculture Limited

    Read More
    Public
  • Argenica begins clinical trials of drug that could protect your brain during a stroke
    • News

    Argenica begins clinical trials of drug that could protect your brain during a stroke

    Every 19 minutes, an Australian suffers a stroke, and every hour that the treatment is delayed, the brain ages up to four years. That paints a rather bleak picture, but that is exactly what biotech company Argenica Therapeutics Limited (ASX: AGN) is addressing as it receives ethics approval from Bellberry’s Human Research Ethics Committee (HREC)

    Read More
    Public
  • Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke
    • News

    Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke

    Aussies suffering from Alzheimer’s disease may have avoided some sketchy science after drug development company Neuroscientific Biopharmaceuticals (ASX: NSB) had their application to commence Phase 1 trials in humans, rejected by the Human Research Ethics Committee (HREC).  In order for any drug development company to commence trials in humans, they must secure HREC approvals which

    Read More
    Public
  • MCS Security acquires traffic management company, aims to grow client base
    • News

    MCS Security acquires traffic management company, aims to grow client base

    In a bid to expand its offerings, security services provider MCS Services (ASX: MSG) has acquired Highways Traffic, a traffic management company based in Western Australia. After signing the Binding Terms Sheet in January 2022, the Company has finally executed a purchase agreement which is subject to operational, licensing and financing pre-conditions. The two companies

    Read More
    Public
  • Hills secures $7m contract for Nurse Call tech in new Footscray Hospital in Melbourne
    • News

    Hills secures $7m contract for Nurse Call tech in new Footscray Hospital in Melbourne

    Addressing Melbourne’s strained public health system, integrated technology distributor Hills (ASX: HIL) has announced that it will be deploying its Nurse Call technology at the new Footscray Hospital, the single largest health infrastructure investment in Victoria. The Company secured the Nurse Call supply and installation contract valued at $7 million, with an option to continue

    Read More
    Public
  • «
  • ‹
  • 336
  • 337
  • 338
  • 339
  • 340
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.